01 / Product stage

Reported evidence

GH001 is investigational inhaled mebufotenin for TRD. GH has completed a randomized Phase 2b study. In its August 6 update, the company described completed device-related Phase 1 work and ongoing FDA discussions on the pivotal program design, with Phase 3 initiation targeted for 2026. A target is not confirmation that Phase 3 has started. [2]

02 / What 57.5% actually means

Reported evidence

The published trial randomized 81 patients: 40 to GH001 and 41 to placebo. At day 8, remission occurred in 23/40 (57.5%) versus 0/41. Remission meant MADRS ≤10; it does not mean a permanent cure. The adjusted difference in score change was −15.5 points (p<.001). This is an encouraging short-term controlled signal, not a head-to-head victory over COMP360. [3]

03 / Short experience, longer visit

My interpretation

Median psychoactive duration was 9, 14 and 11.5 minutes at the three dose levels. Individual durations varied; dosing could occur up to three times, one hour apart, with professional supervision. My inference is that short drug effects may help throughput, but the full appointment also includes screening, repeat dosing and observation. Price, staffing and reimbursement remain necessary inputs. [3]

04 / Cash position

Reported evidence

At June 30, 2026, cash, cash equivalents and marketable securities totaled $362.7 million. This includes securities and should not be mislabeled as cash alone. I do not infer a fixed runway by dividing this balance by one quarter of accounting loss; Phase 3 spending can change. [2]

05 / Financing and what remains uncertain

Reported evidence

The April offering priced 6,527,779 new ordinary shares at $18, for approximately $117.5 million gross before fees. New shares expand the denominator of ownership. I will track pivotal trial initiation, durability with repeat treatment, safety in a larger population and the complete clinic workflow. [7]

The evidence still has limits

My interpretation

Psychoactive effects can let patients guess treatment assignment, a problem called functional unblinding. Independent blinded raters help, but do not erase it. The trial also had a small sample and short controlled follow-up. A promising result is a reason for a better next trial, rather than certainty about routine clinical use.

Sources

Plain-text references. Financial balances are dated June 30, 2026; source review completed October 6, 2026.

  1. GH Research. Second Quarter 2026 Financial Results and Business Update. August 6, 2026.
  2. Cubała WJ, Bajbouj M, Bauer M, et al. GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2026;83(6):561–569. DOI: 10.1001/jamapsychiatry.2026.0096.
  3. GH Research. Pricing of $117.5 Million Underwritten Offering. April 29, 2026.